Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.

SEC Filings

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

Filing date	Description	Form	Filing Group	View
Mar 06, 2023	Report of unscheduled material events or corporate event	8-K	Current Reports	0001104659-23-028736.pdf 0001104659-23-028736.rtf 0001104659-23-028736.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Mar 10, 2023	Report of unscheduled material events or corporate event	8-K	Current Reports	0000950170-23-007327.pdf 0000950170-23-007327.rtf 0000950170-23-007327.xls EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT View HTML
Mar 23, 2023	Report of unscheduled material events or corporate event	8-K	Current Reports	0000950170-23-009310.pdf 0000950170-23-009310.rtf 0000950170-23-009310.xls EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT View HTML
May 11, 2023	Report of unscheduled material events or corporate event	8-K	Current Reports	0000950170-23-020817.pdf 0000950170-23-020817.rtf 0000950170-23-020817.xls EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT View HTML
May 22, 2023	Report of unscheduled material events or corporate event	8-K	Current Reports	0001104659-23-062923.pdf 0001104659-23-062923.rtf 0001104659-23-062923.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
May 24, 2023	Report of unscheduled material events or corporate event	8-K	Current Reports	0001193125-23-153015.pdf 0001193125-23-153015.rtf 0001193125-23-153015.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
May 30, 2023	Report of unscheduled material events or corporate event	8-K	Current Reports	0001104659-23-066044.pdf 0001104659-23-066044.rtf 0001104659-23-066044.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Jun 01, 2023	Report of unscheduled material events or corporate event	8-K	Current Reports	0001104659-23-067031.pdf 0001104659-23-067031.rtf EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML
Dec 28, 2018	Registration statement for face-amount certificate companies	S-1	Registration Statements	0001193125-18-360714.pdf 0001193125-18-360714.rtf 0001193125-18-360714.xls View HTML
Jan 19, 2021	Registration of up to an additional 20% of securities for any offering registered on a S-3	S-3MEF	Registration Statements	0001193125-21-011747.pdf 0001193125-21-011747.rtf 0001193125-21-011747.xls View HTML

Data provided by Kaleidoscope.

Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.